logo

For the Inventor, By the Inventor

Aachen, Germany

Grunenthal Gmbh


USPTO Granted Patents = 107

% Expired Patents = 61.7



Forward Citations = 996

Loading Chart...
Loading Chart...

187 inventors (with patents filed for the assignee):

goldMedal Johannes Bartholomäus (18 out of 28 patents)

silverMedal Florian Jakob (15 out of 27 patents)

bronzeMedal Heinrich Kugelmann (14 out of 22 patents)

4.  Lutz Barnscheid (13 out of 18 patents)

5.  Achim Kless (12 out of 30 patents)

6.  Stefan Schunk (12 out of 36 patents)

7.  Paul Ratcliffe (11 out of 15 patents)

8.  Ingo Konetzki (10 out of 16 patents)

9.  Wolfgang Schröder (10 out of 25 patents)

10.  Sebastian Schwier (9 out of 12 patents)

11.  Tobias Craan (9 out of 14 patents)

12.  Melanie Reich (8 out of 34 patents)

13.  Gregor Bahrenberg (8 out of 46 patents)

14.  Simon Lucas (8 out of 12 patents)

15.  Werner Guenter Englberger (8 out of 58 patents)


Core Competencies:
Tamper Resistant
Abuse-Proofed
Pharmaceutical Dosage Forms
Pain Treatment
Triazolo Quinoxaline
Pyrazole Amides
KCNQ2/3 Modulators
Stable Formulations
Chronic Pain Inhibition
Crystallization Methods
Drug Release
Formulation Stability

107 patents:

1. 12358907 - Substituted pyrrolidine amides III (2025-07-15),
2. 12110293 - Substituted triazolo quinoxaline derivatives (2024-10-08),
3. 11999699 - Substituted pyrazole amides (2024-06-04),
4. 11981677 - Further substituted triazolo quinoxaline derivatives (2024-05-14),
5. 11844865 - Abuse-proofed oral dosage form (2023-12-19),
6. 11739049 - Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (2023-08-29),
7. 11344512 - Titration of tapentadol (2022-05-31),
8. 11224576 - Process for the production of an abuse-proofed dosage form (2022-01-18),
9. 11013701 - Stable formulation for parenteral administration of tapentadol (2021-05-25),
10. 10981918 - Further substituted triazolo quinoxaline derivatives (2021-04-20),
11. 10912763 - Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine (2021-02-09),
12. 10864164 - Tamper-resistant tablet providing immediate drug release (2020-12-15),
13. 10842750 - Protecting oral overdose with abuse deterrent immediate release formulations (2020-11-24),
14. 10813891 - Method of inhibiting chronification of pain (2020-10-27),
15. 10813890 - Pharmaceutical combination (2020-10-27),
GRUNENTHAL GMBH is a pharmaceutical company based in Germany. They specialize in the research, development, and marketing of innovative therapies for patients with severe and debilitating diseases. With a focus on pain management and therapeutics, GRUNENTHAL GMBH strives to improve the quality of life for patients globally. For more information, please visit their official website.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Grunenthal Gmbh
107 Patents

#4 in Aachen

#554 in Germany

#7,326 in the World

Aachen, DE
Aachen, Germany

Grunenthal Gmbh

Forward Citations = 996

187 inventors:

goldMedal Johannes Bartholomäus (18 out of 28 patents)

silverMedal Florian Jakob (15 out of 27 patents)

bronzeMedal Heinrich Kugelmann (14 out of 22 patents)

4.  Lutz Barnscheid (13 out of 18 patents)

5.  Achim Kless (12 out of 30 patents)

Please report any incorrect information to [email protected]
Loading…